Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial

This trial met its primary objective, regorafenib significantly delayed disease progression after first-line treatment in advanced non-adipocytic STS. This was associated with a non-significant trend of overall survival improvement.

Authors

Institutions

Publication Details

Journal
Annals of Oncology
Published
2025-04-08
DOI
https://doi.org/10.1016/j.annonc.2025.03.024
Citations
3
Primary Topic
Sarcoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
4.56
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial

L. Chaigneau, B. Verret, Thomas Ryckewaert, Angélique Brunot et al.
3 citations
Annals of Oncology
Sarcoma Diagnosis and Treatment
4.56
article

Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial

L. Chaigneau, B. Verret, Thomas Ryckewaert, Angélique Brunot, Sarah Watson, Nelly Firmin, Marie‐Cécile Le Deley, Jean‐Yves Blay, Christophe Perrin, Jennifer Wallet, Nicolas Penel, Marie Vanseymortier, Antoîne Italiano, Thibaud Valentin, Clémence Henon, Mariella Spalato Ceruso, Mehdi Brahmi, Emmanuelle Bompas, François Bertucci, E Heyman-Decoupigny
article en
3 citations

Abstract

This trial met its primary objective, regorafenib significantly delayed disease progression after first-line treatment in advanced non-adipocytic STS. This was associated with a non-significant trend of overall survival improvement.

Annals of OncologyVol. 36(8)
Université Claude Bernard Lyon 1 (FR), Université Paris-Sud (FR), Inserm (FR), Université de Versailles Saint-Quentin-en-Yvelines (FR), Université Paris Sciences et Lettres (FR), Université Paris-Saclay (FR), Institut Gustave Roussy (FR), Institut universitaire du cancer de Toulouse Oncopole (FR), Centre de recherche en Epidémiologie et Santé des Populations (FR), Centre Léon Bérard (FR), Institut de Cancérologie de l'Ouest (FR), Centre Eugène Marquis (FR), Centre Oscar Lambret (FR), Institut Bergonié (FR), Institut de Recherche en Cancérologie de Montpellier (FR), Institut Paoli-Calmettes (FR), Université de Franche-Comté (FR)
Good health and well-being
Openalex Percentile: Top 6%
Sarcoma Diagnosis and Treatment
4.56
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.